EMAIL
PRINT
32 COMMENTSShare & save this story:
Also in DrugReporter
The Purple Brain: America's New Reefer Madness
Marsha Rosenbaum, Paul Armentano
The Futility of Random Drug Testing
Marsha Rosenbaum
Media Hype About Painkillers Shot Down
Dani McClain
New York Must Reform Its Racist Drug Laws
Gabriel Sayegh
New Studies Destroy the Last Objection to Medical Marijuana
Bruce Mirken
An independent U.S. Food and Drug Administration advisory committee determined yesterday that the controversial "anti-pot" pill Rimonabant is unsafe for human consumption in the United States. Sanofi-Aventis' would-be diet aid -- which has been linked to suicidal thoughts, depression and even multiple sclerosis -- counteracts the effects of marijuana and similar naturally occurring chemicals in the body (so-called endocannabinoids), causing users to lose their appetites and, according to the warnings of experts, a host of other unwanted and dangerous side effects.
Rimonabant does not possess a "favorable risk-benefit profile" to warrant U.S. market approval, members of the FDA's Endocrinologic and Metabolic Drug advisory panel determined in a 14-0 vote. Panelists reported that patients prescribed Rimonabant experienced increased incidences of depression, nausea, vomiting, and suicidal tendencies. Adverse neurological symptoms in some patients were also reported.
The expert panel's rejection sent shares of Sanofi stock plummeting and may have worldwide implications. Last summer European regulators gave preliminary approval to the pill, which has now been prescribed to some 100,000 patients under the trade name Acomplia. However, following Wednesday's unanimous decision, representatives of the European Medicines Agency immediately announced that they will begin hearings to consider recalling the drug.
For Sanofi stockholders and analysts, who had predicted that pharmaceutical giant's "anti-pot" pill could one day rake in some $3 billion in annual profits, the news is a disappointing financial setback. But to health experts familiar with the workings of Rimonabant and similar drugs, the FDA panel's decision comes as little surprise and is long overdue.
The dark side of Acomplia
As a weight loss drug, Rimonabant is far from a miracle cure. In controlled studies, patients who ceased taking Rimonabant typically gained their weight back -- implying that the drug may have to be prescribed indefinitely. It's that likelihood, coupled with the drug's reported and potential side effects, that have raised eyebrows among the scientific community.
Because the endocannabinoid system is involved in the regulation of a broad range of primary biological functions -- including appetite, mood regulation, blood pressure, bone density, reproduction, learning capacity, and motor coordination -- some experts are concerned that the long-term use of Rimonabant and/or similar drugs to counteract it could contribute to a host of significant adverse health effects. Animal data appears to substantiate this concern. Newborn mice injected with Rimonabant refuse feeding and often die days after birth. Mice genetically bred to lack certain cannabinoid receptors also suffer from numerous health defects such as cognitive decline, hypoalgesia, decreased locomotor activity and increased mortality compared to healthy controls. Could similar risks await long-term users of Rimonabant?
See more stories tagged with: anti-pot, rimonabant
Paul Armentano is the senior policy analyst for the NORML Foundation in Washington, D.C.
No comments:
Post a Comment